Kadir Rais Reskiawan A, Alwjwaj Mansour, Bayraktutan Ulvi
Academic Unit of Mental Health and Clinical Neuroscience, School of Medicine, The University of Nottingham, Nottingham, UK.
Academic Unit of Mental Health and Clinical Neuroscience, School of Medicine, The University of Nottingham, Nottingham, UK.
Cytotherapy. 2022 May;24(5):489-499. doi: 10.1016/j.jcyt.2021.11.005. Epub 2022 Feb 16.
We have previously reported that outgrowth endothelial cells (OECs) restore cerebral endothelial cell integrity through effective homing to the injury site. This study further investigates whether treatment with OECs can restore blood-brain barrier (BBB) function in settings of ischemia-reperfusion injury both in vitro and in vivo.
An in vitro model of human BBB was established by co-culture of astrocytes, pericytes, and human brain microvascular endothelial cells (HBMECs) before exposure to oxygen-glucose deprivation alone or followed by reperfusion (OGD±R) in the absence or presence of exogenous OECs. Using a rodent model of middle cerebral artery occlusion (MCAO), we further assessed the therapeutic potential of OECs in vivo.
Owing to their prominent antioxidant, proliferative, and migratory properties, alongside their inherent capacity to incorporate into brain vasculature, treatments with OECs attenuated the extent of OGD±R injury on BBB integrity and function, as ascertained by increases in transendothelial electrical resistance and decreases in paracellular flux across the barrier. Similarly, intravenous delivery of OECs also led to better barrier protection in MCAO rats as evidenced by significant decreases in ipsilateral brain edema volumes on day 3 after treatment. Mechanistic studies subsequently showed that treatment with OECs substantially reduced oxidative stress and apoptosis in HBMECs subjected to ischemic damages.
This experimental study shows that OEC-based cell therapy restores BBB integrity in an effective manner by integrating into resident cerebral microvascular network, suppressing oxidative stress and cellular apoptosis.
我们之前报道过,血管生成内皮细胞(OECs)通过有效归巢至损伤部位来恢复脑内皮细胞的完整性。本研究进一步探讨在体外和体内的缺血再灌注损伤情况下,用OECs进行治疗是否能恢复血脑屏障(BBB)功能。
通过将星形胶质细胞、周细胞与人脑微血管内皮细胞(HBMECs)共培养,建立人血脑屏障的体外模型,然后单独暴露于氧葡萄糖剥夺或在有无外源性OECs的情况下进行再灌注(OGD±R)。使用大鼠大脑中动脉闭塞(MCAO)模型,我们进一步评估了OECs在体内的治疗潜力。
由于其显著的抗氧化、增殖和迁移特性,以及其整合到脑血管系统中的固有能力,用OECs进行治疗减弱了OGD±R对血脑屏障完整性和功能的损伤程度,这通过跨内皮电阻的增加和屏障旁细胞通量的减少得以确定。同样,静脉注射OECs也能在MCAO大鼠中提供更好的屏障保护,治疗后第3天同侧脑水肿体积显著减少证明了这一点。随后的机制研究表明,用OECs进行治疗可显著降低遭受缺血损伤的HBMECs中的氧化应激和细胞凋亡。
本实验研究表明,基于OECs的细胞疗法通过整合到驻留的脑微血管网络中、抑制氧化应激和细胞凋亡,以有效方式恢复血脑屏障的完整性。